Overview

Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures

Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Stanford University
Treatments:
Panitumumab